Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.
The authors administered repeated courses of intravenous immunoglobulin (IVIg) to nine patients at the onset of an exacerbation of generalized myasthenia gravis (MG). Anticholinesterase medication (nine patients) and corticosteroid dosage (six patients) had been kept constant for a 2-month period. Six patients received two courses, two patients received three courses, and one patient received five courses. Twenty of 23 courses resulted in satisfactory improvement beginning 4.3 +/- 1.2 days after start of IVIg and becoming maximal 8.2 +/- 2.0 days, with sustained improvement lasting 106.6 +/- 49.1 days. Vital capacity increased from an average of 1845.1 +/- 489 cc to 2894 +/- 762 cc (p less than 0.01) at peak effect. Four of nine patients had a decrease in strength before improvement. There was no significant change in acetylcholine receptor antibody titers before or after therapy. Side effects were minimal. Of the three patients who had nonsatisfactory course, two responded well to additional IVIg. IVIg can produce repeated beneficial effects in patients with MG and may be useful as an adjunct in the management of MG.
Arsura
E L
EL
State University of New York Health Science Center, Brooklyn.
Bick
A
A
Brunner
N G
NG
Grob
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D004306:Dose-Response Relationship, Immunologic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007136:Immunoglobulins / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000628:therapy*; D009388:Neostigmine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011729:Pyridostigmine Bromide / Q000008:administration & dosage
D007136:Immunoglobulins; D009388:Neostigmine; D011729:Pyridostigmine Bromide; D011241:Prednisone